Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 5, 2007, Pages 458-463

  Bakker, Jaap A ^a   Drent, Marjolein ^a   Bierau, Jörgen ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adverse drug events; Inosine triphosphate pyrophosphohydrolase; Mercaptopurine metabolism; Pharmacogenetic screening; Thiopurine methyltransferase

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; INORGANIC PYROPHOSPHATASE; INOSINE TRIPHOSPHATE; MERCAPTOPURINE; METHOTREXATE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AUTOIMMUNE DISEASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; ENTERITIS; ENZYME ACTIVITY; ENZYME DEFICIENCY; EYE INFLAMMATION; GENETIC DISORDER; GENETIC SCREENING; HEALTH CARE COST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; PHARMACOGENETICS; REVIEW; SKIN DISEASE;

6-MERCAPTOPURINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MASS SCREENING; PHARMACOGENETICS;

EID: 34748835879     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328273bc18     Document Type: Review

References (61)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277-304.
2. Martinez FJ. Idiopathic interstitial pneumonias: usual interstitial pneumonia versus nonspecific interstitial pneumonia. Proc Am Thorac Soc 2006; 3:81-95. •• Excellent overview of the diagnosis and treatment options for idiopathic interstitial pneumonia.
3. Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003:CD003134.
4. Hull JH. Acetylcysteine in pulmonary fibrosis. N Engl J Med 2006; 354:1089-1091.
5. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229-2242.
6. Shah NR, Noble P, Jackson RM, et al. A critical assessment of treatment options for idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22:167-174.
7. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144:291-296.
8. Drent M, du Bois RM, Poletti V. Recent advances in the diagnosis and management of nonspecific interstitial pneumonia. Curr Opin Pulm Med 2003; 9:411-417.
9. Sanderson J, Ansari A, Marinaki T, Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem 2004; 41:294-302.
10. Ferraccioli G, De Santis M, Tolusso B. Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology. Pharmacogenomics 2004; 5:1107-1116.
11. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348:529-537.
12. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
13. Hiratsuka M, Sasaki T, MizugakiM. Genetic testing for pharmacogenetics and its clinical application in drug therapy. Clin Chim Acta 2006; 363:177-186.
14. Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24:715-729. •• Recent review on the use of thiopurines in inflammatory bowel disease and the possible strategies to optimize mercaptopurine therapy.
15. Banerjee S, Bishop WP. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center. J Pediatr Gastroenterol Nutr 2006; 43:324-330. • The focus of this paper is on the pediatric use of mercaptopurines in inflammatory bowel disease.
16. Clunie GP, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology (Oxford) 2004; 43:13-18.
17. Gauba V, Saldanha M, Vize C, Saleh GM. Thiopurine methyltransferase screening before azathioprine therapy. Br J Ophthalmol 2006; 90:923-924. • Short report on the use of mercaptopurine therapy in ophthalmology.
18. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006; 367:839-846. • Well designed study on the efficacy of mercaptopurine therapy in patients with atopic eczema.
19. Coulthard SA, Hogarth LA, Little M, et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol Pharmacol 2002; 62:102-109.
20. Kitchen BJ, Moser A, Lowe E, et al. Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy-thioguanine. J Pharmacol Exp Ther 1999; 291:870-874.
21. Duley JA, Florin TH. Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther Drug Monit 2005; 27:647-654.
22. Breen DP, Marinaki AM, Arenas M, Hayes PC. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl 2005; 11:826-833.
23. Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002; 111:360-367.
24. Brouwer C, Vogels-Mentink TM, Keizer-Garritsen JJ, et al. Role of 5′-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment. Clin Chim Acta 2005; 361:95-103.
25. Stocco G, Martelossi S, Barabino A, et al. Glutathione-S- transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:57-64. •• Excellent paper on the role of glutathione-S-transferase mutations and the therapeutic efficacy of mercaptopurine therapy.
26. McGovern DP, Travis SP, Duley J, et al. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 2002; 122:838-839.
27. Fotoohi AK, Wrabel A, Moshfegh A, et al. Molecular mechanisms underlying the enhanced sensitivity of thiopurine-resistant T-lymphoblastic cell lines to methyl mercaptopurineriboside. Biochem Pharmacol 2006; 72:816-823. •• This paper opens a complete new field in mercaptopurine research by describing the role of transporters in cellular transport of mercaptopurine and its metabolites.
28. Bemi V, Turchi G, Margotti E, et al. 6-Thioguanine resistance in a human colon carcinoma cell line with unaltered levels of hypoxanthine guanine phosphoribosyltransferase activity. Int J Cancer 1999; 82:556-561.
29. Giverhaug T, Loennechen T, Aarbakke J. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX). Gen Pharmacol 1999; 33:341-346.
30. Chocair P, Duley J, Simmonds HA, et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 1993; 342:83-84.
31. Weinshilboum RM. Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase. Cell Mol Neurobiol 2006; 26:539-561. •• In this outstanding paper the clinical relevance of methyltransferases in human metabolism is described in pharmacogenetic terms.
32. Gunnarsdottir S, Elfarra AA. Distinct tissue distribution of metabolites of the novel glutathione-activated thiopurine prodrugs cis-6-(2-acetylvinylthio) purine and trans-6-(2-acetylvinylthio)guanine and 6-thioguanine in the mouse. Drug Metab Dispos 2003; 31:718-726.
33. Derijks LJ, Gilissen LP, de Boer NK, Mulder CJ. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent? J Hepatol 2006; 44:821-822. • The relation between thioguanine nucleotides and hepatic toxicity is described in patients on mercaptopurine therapy.
34. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705-713.
35. Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. Annu Rev Med 2003; 54:437-452.
36. Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 2004; 75:274-281.
37. Gilissen LP, Derijks LJ, Verhoeven HM, et al. Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease. Dig Liver Dis 2007; 39:182-186. • This paper describes the role of methylmercaptopurines in patients with pancytopenia due to mercaptopurine therapy.
38. Tay BS, Lilley RM, Murray AW, Atkinson MR. Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides. Biochem Pharmacol 1969; 18:936-938.
39. Zelinkova Z, Derijks LJ, Stokkers PC, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 2006; 4:44-49. • The association between TPMT and ITPase polymorphisms and myelosuppression is investigated.
40. Gardiner SJ, Gearry RB, Barclay ML, Begg EJ. Two cases of thiopurine methyltransferase (TPMT) deficiency: a lucky save and a near miss with azathioprine. Br J Clin Pharmacol 2006; 62:473-476. • In this short case report the clinical relevance of measuring for TPMT activity before starting mercaptopurine therapy is illustrated.
41. Armstrong VW, Shipkova M, von Ahsen N, Oellerich M. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit 2004; 26:220-226.
42. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14:181-187.
43. Maeda T, Sumi S, Ueta A, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab 2005; 85:271-279.
44. Shipkova M, Lorenz K, Oellerich M, et al. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem 2006; 52:240-247. • Characteristics of the Caucasian population for ITPase are described in this paper.
45. Bierau J, Bakker JA, Lindhout M, van Gennip AH. Determination of ITPase activity in erythrocyte lysates obtained for determination of TPMT activity. Nucleosides Nucleotides Nucleic Acids 2006; 25:1129-1132. • Methodological paper on the determination of ITPase in human erythrocyte lysate.
46. van Dieren JM, van Vuuren AJ, Kusters JG, et al. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut 2005; 54:1664.
47. Allorge D, Hamdan R, Broly F, et al. ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6- mercaptopurine induced myelosuppression. Gut 2005; 54:565.
48. Marinaki AM, Duley JA, Arenas M, et al. Mutation in the ITPA gene predicts intolerance to azathioprine. Nucleosides Nucleotides Nucleic Acids 2004; 23:1393-1397.
49. von Ahsen N, Armstrong VW, Behrens C, et al. Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem 2005; 51:2282-2288.
50. Kerstens PJ, Stolk JN, De Abreu RA, et al. Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:142-145.
51. Kerstens PJ, Stolk JN, Hilbrands LB, et al. 5-Nucleotidase and azathioprine-related bone-marrow toxicity. Lancet 1993; 342:1245-1246.
52. Goldsmith D, Carrey EA, Edbury S, et al. Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond) 2004; 107:63-68.
53. Goldsmith DJ, Carrey EA, Edbury SM, et al. GTP concentrations are elevated in erythrocytes of renal transplant recipients when conventional immunosuppression is replaced by the inosine monophosphate dehydrogenase inhibitor mycophenolic acid mofetil (MMF). Nucleosides Nucleotides Nucleic Acids 2004; 23:1407-1409.
54. Roberts RL, Gearry RB, Barclay ML, Kennedy MA. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J 2006; 26 September [Epub ahead of print]. • The first description of the role of IMPDH in mercaptopurine therapy.
55. Nakamura J, Lou L. Biochemical characterization of human GMP synthetase. J Biol Chem 1995; 270:7347-7353.
56. Anglicheau D, Sanquer S, Loriot MA, et al. Thiopurine methyltransferase activity: new conditions for reversed-phase high-performance liquid chromatographic assay without extraction and genotypic-phenotypic correlation. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 773:119-127.
57. van den Akker-van Marle ME, Gurwitz D, Detmar SB, et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 2006; 7:783-792. •• Study on the cost-effectiveness of pharmacogenomic analysis in several countries in the European Community.
58. Priest VL, Begg EJ,Gardiner SJ, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 2006; 24:767-781. •• A study on the cost-effectiveness of prospective testing of TPMT and clinical follow up in inflammatory bowel disease patients.
59. Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20:593-599.
60. van Delden J, Bolt I, Kalis A, et al. Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics. Bioethics 2004; 18:303-321.
61. Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics 2005; 15:365-369.